BIOMARIN PHARMACEUTICAL INC.

ISIN: **US09061G1013** WKN: **09061G101** Asset Class: Stock

100.00 Company 2024/04/10 22:00:00 **Price** 95.00 90.21 **B**IOMARIN USD 90.00 **Difference** 1.38%(1.23) 85.00 **Contact Details** 80.00 **BIOMARIN** Tel: (415) 884-6700 PHARMACEUTICAL INC. 75.00

05.2023 07.2023 09.202311.2023 01.2024 03.2024

371 Bel Marin Keys Blvd.,

Suite 210

CA 94949 Novato

Web:

http://www.biomarinpharm.com

Fax: (415) 382-7889

E-mail:

webmaster@biomarinpharm.com

Company Profile

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and lifethreatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Financial figures, Fiscal year: from 01.01. to 31.12.						
Financial figures	2023 Assets Liabilities and equity		2022 Assets Liabilities and equity		2021 Assets Liabilities and equity	
Current assets	-		-		-	
Common stock capital		-		-		
Fixed assets	-		-		-	
Equity capital of a company		-		-		
Cash and cash equivalents	-		-		-	
Accrued liabilities		-		-		
Other assets	-		-		-	
Current liabilities		-		-		
Prepayments and accrued income	-		-		-	
Non-current liabilities		-		-		
Different income		-		-		
Other liabilities		-		-		
Total assets		_				

Total assets	-	-	-	-	
Polones notes					
Balance notes					
			2023	2022	2021
Accounting standard			-	-	-
Employees			-	-	-
Equity ratio			72.37%	72.21%	71.14%
Debt-equity ratio			38.17%	38.49%	40.57%
Others					
			2023	2022	2021
Tax Expense Rate			11.09%	5.36%	14.96%

BIOMARIN PHARMACEUTICAL INC.

ISIN: US09061G1013 WKN: 09061G101 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	-	-	-
Net income	-	-	-
EBIT	136,255,981	136,212,581	-65,095,083
Operating income before taxes	-	-	-
Cash Flow	-	-	-
Net interest income	-	-	-
Research and development expenses	-	-	-
Income taxes	-	-	-
Result from investments in subsidaries, associates and other	-	-	-
Revenues per employee	656,891	613,452	559,826

Board of Directors

Members of Management Board		
Richard Meier	Chairman of Board of Directors	
Athena Countouriotis	Member of Board of Directors	
Dennis Slamon	Member of Board of Directors	
Elaine Heron	Member of Board of Directors	
May Kin Ho	Member of Board of Directors	
V. Lawlis	Member of Board of Directors	
Willard Dere	Member of Board of Directors	
Barbara Bodem	Member of Board of Directors	
David Pyott	Member of Board of Directors	
Elizabeth Anderson	Member of Board of Directors	
Jean-Jacques Bienaimé	Member of Board of Directors	
Mark Alles	Member of Board of Directors	
Mark Enyedy	Member of Board of Directors	
Robert Hombach	Member of Board of Directors	
Jean-Jacques Bienaimé	Chairman of Managing Board	
Brinda Balakrishnan	Member of Executive Committee	
C. Greg Guyer	Member of Executive Committee	
Amy Wireman	Member of Executive Committee	
Brian Mueller	Member of Executive Committee	
G. Eric Davis	Member of Executive Committee	
Henry J. Fuchs	Member of Executive Committee	
Jeff Ajer	Member of Executive Committee	
Philip Lo Scalzo	Member of Executive Committee	